Thu, Apr 21, 2022 11:00 AM – 12:00 PM EDT Register>> There has been substantial recent progress in new heart failure (HF) treatments, yet there is still a large unmet need in the treatment of HF with preserved, mid-range, and reduced ejection fraction as well those with co-morbidities. Linked real-world data (RWD) can provide a[…]
Read the Press Release>> BOSTON, March 31, 2022 /PRNewswire/ — OM1, a leading technology enabled real-world data and artificial intelligence (AI) company with a focus on delivering insights into multiple chronic diseases, today announces the launch of its Mental Health and Neuroscience Specialty Area led by physician and entrepreneur, Dr. Carl D. Marci. The division includes new data on psychiatric[…]
Pharmaceutical Executive Online Published: March 15, 2022 Read the Full Article >> If you were asked which health care conditions rank as the highest in both unmet need and in cost, which would you choose? Would it be cancer or heart disease? While those conditions certainly place in both categories, mental health outranks them in[…]
OM1’s Dr. Richard Gliklich presents on leveraging the AAO-HFN Reg-ent Registry for research at the FDA-MDEpiNet conference “Cochlear Implant Innovation, Research and Advancement (CIRCA). View Agenda >>
Tue, Jan 25, 2022 12:30 PM – 1:30 PM EST Presenter: Rich Gliklich, CEO, OM1 Register >> Real-World Data (RWD) and Artificial Intelligence (AI) applications are rapidly growing in importance in R&D for Chronic and Immune-mediated Diseases. Join us as we explore: Data Networks The ‘Unstructured’ Medical Record Hybrid Data Collection Data Linkage Artificial Intelligence[…]
